

Filipe B. Rodrigues

List of Publications by Citations

Source: <https://exaly.com/author-pdf/5061323/filipe-b-rodrigues-publications-by-citations.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

74
papers

1,344
citations

19
h-index

35
g-index

94
ext. papers

1,821
ext. citations

5.3
avg, IF

4.98
L-index

#	Paper	IF	Citations
74	Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis. <i>Lancet Neurology, The</i> , 2017 , 16, 601-609	24.1	172
73	Endovascular treatment versus medical care alone for ischaemic stroke: systematic review and meta-analysis. <i>BMJ, The</i> , 2016 , 353, i1754	5.9	120
72	Non-vitamin K antagonist oral anticoagulants and major bleeding-related fatality in patients with atrial fibrillation and venous thromboembolism: a systematic review and meta-analysis. <i>Heart</i> , 2015 , 101, 1204-11	5.1	87
71	Deep brain stimulation for dystonia. <i>The Cochrane Library</i> , 2016 ,	5.2	78
70	Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington's disease. <i>Science Translational Medicine</i> , 2018 , 10,	17.5	67
69	Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington's disease Young Adult Study (HD-YAS): a cross-sectional analysis. <i>Lancet Neurology, The</i> , 2020 , 19, 502-512	24.1	56
68	Neurofilament light protein in blood predicts regional atrophy in Huntington disease. <i>Neurology</i> , 2018 , 90, e717-e723	6.5	42
67	Fifteen Years of Clinical Trials in Huntington's Disease: A Very Low Clinical Drug Development Success Rate. <i>Journal of Huntingtons Disease</i> , 2017 , 6, 157-163	1.9	39
66	Survival, Mortality, Causes and Places of Death in a European Huntington's Disease Prospective Cohort. <i>Movement Disorders Clinical Practice</i> , 2017 , 4, 737-742	2.2	38
65	Cerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington's disease. <i>Journal of Neurochemistry</i> , 2016 , 139, 22-5	6	37
64	Huntington's Disease Clinical Trials Corner: February 2018. <i>Journal of Huntingtons Disease</i> , 2018 , 7, 89-98	1.9	36
63	Placebo and nocebo responses in restless legs syndrome: A systematic review and meta-analysis. <i>Neurology</i> , 2017 , 88, 2216-2224	6.5	35
62	Cerebrospinal Fluid Inflammatory Biomarkers Reflect Clinical Severity in Huntington's Disease. <i>PLoS ONE</i> , 2016 , 11, e0163479	3.7	35
61	Botulinum toxin type A therapy for cervical dystonia. <i>The Cochrane Library</i> , 2017 , 12, CD003633	5.2	34
60	Tetrabenazine Versus Deutetabenazine for Huntington's Disease: Twins or Distant Cousins?. <i>Movement Disorders Clinical Practice</i> , 2017 , 4, 582-585	2.2	31
59	Clinical Trials Corner: September 2017. <i>Journal of Huntingtons Disease</i> , 2017 , 6, 255-263	1.9	28
58	Huntington's Disease Clinical Trials Corner: April 2020. <i>Journal of Huntingtons Disease</i> , 2020 , 9, 185-197	1.9	24

57	Mutant huntingtin and neurofilament light have distinct longitudinal dynamics in Huntington's disease. <i>Science Translational Medicine</i> , 2020 , 12,	17.5	24
56	Deep brain stimulation for dystonia. <i>The Cochrane Library</i> , 2019 , 1, CD012405	5.2	23
55	Huntington's Disease Clinical Trials Corner: January 2019. <i>Journal of Huntingtons Disease</i> , 2019 , 8, 115-125	1.9	19
54	Botulinum toxin type A versus botulinum toxin type B for cervical dystonia. <i>The Cochrane Library</i> , 2016 , 10, CD004314	5.2	19
53	Botulinum toxin type B for cervical dystonia. <i>The Cochrane Library</i> , 2016 , CD004315	5.2	19
52	Huntington's Disease Clinical Trials Corner: June 2019. <i>Journal of Huntingtons Disease</i> , 2019 , 8, 363-371	1.9	18
51	Cerebrospinal fluid neurogranin and TREM2 in Huntington's disease. <i>Scientific Reports</i> , 2018 , 8, 4260	4.9	17
50	Huntington's Disease Clinical Trials Corner: August 2018. <i>Journal of Huntingtons Disease</i> , 2018 , 7, 279-286	1.9	17
49	Anti-TNF Drugs for Chronic Uveitis in Adults-A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Frontiers in Medicine</i> , 2019 , 6, 104	4.9	15
48	Efficacy and safety of intravitreal anti-tumour necrosis factor drugs in adults with non-infectious uveitis - a systematic review. <i>Acta Ophthalmologica</i> , 2018 , 96, e665-e675	3.7	13
47	Intracerebral hemorrhage as a manifestation of cerebral hyperperfusion syndrome after carotid revascularization: systematic review and meta-analysis. <i>Acta Neurochirurgica</i> , 2017 , 159, 2089-2097	3	13
46	Cardiac Harms of Sofosbuvir: Systematic Review and Meta-Analysis. <i>Drug Safety</i> , 2018 , 41, 77-86	5.1	13
45	Biofluid Biomarkers in Huntington's Disease. <i>Methods in Molecular Biology</i> , 2018 , 1780, 329-396	1.4	13
44	Morphine in acute coronary syndrome: systematic review and meta-analysis. <i>BMJ Open</i> , 2019 , 9, e025233	2.2	12
43	Rating Scales and Performance-based Measures for Assessment of Functional Ability in Huntington's Disease: Critique and Recommendations. <i>Movement Disorders Clinical Practice</i> , 2018 , 5, 361-372	2.2	12
42	Quality of Life in Huntington's Disease: Critique and Recommendations for Measures Assessing Patient Health-Related Quality of Life and Caregiver Quality of Life. <i>Movement Disorders</i> , 2018 , 33, 742-749	7.49	12
41	Opicapone for the treatment of Parkinson's disease. <i>Expert Opinion on Pharmacotherapy</i> , 2017 , 18, 445-453	4.53	11
40	Comparison of the Huntington's Disease like 2 and Huntington's Disease Clinical Phenotypes. <i>Movement Disorders Clinical Practice</i> , 2019 , 6, 302-311	2.2	9

39	Meta-research metrics matter: letter regarding article "indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease". <i>Journal of Clinical Movement Disorders</i> , 2017 , 4, 19	2.8	8
38	Autosomal dominant polycystic kidney disease and coronary artery dissection or aneurysm: a systematic review. <i>Renal Failure</i> , 2016 , 38, 493-502	2.9	8
37	Adverse events with botulinum toxin treatment in cervical dystonia: How much should we blame placebo?. <i>Parkinsonism and Related Disorders</i> , 2018 , 56, 16-19	3.6	8
36	The use of wearable/portable digital sensors in Huntington's disease: A systematic review. <i>Parkinsonism and Related Disorders</i> , 2021 , 83, 93-104	3.6	8
35	Botulinum toxin type A therapy for cervical dystonia. <i>The Cochrane Library</i> , 2020 , 11, CD003633	5.2	7
34	Characterizing White Matter in Huntington's Disease. <i>Movement Disorders Clinical Practice</i> , 2020 , 7, 52-60.	2	6
33	Thromboprophylaxis With Apixaban in Patients Undergoing Major Orthopedic Surgery: Meta-Analysis and Trial-Sequential Analysis. <i>Clinical Medicine Insights Blood Disorders</i> , 2017 , 10, 1179545X17704660	2	5
32	Extended daily dialysis versus intermittent hemodialysis for acute kidney injury: A systematic review. <i>Journal of Critical Care</i> , 2016 , 33, 271-3	4	5
31	Botulinum toxin type A therapy for blepharospasm. <i>The Cochrane Library</i> , 2020 , 11, CD004900	5.2	5
30	Kynurenine pathway metabolites in cerebrospinal fluid and blood as potential biomarkers in Huntington's disease. <i>Journal of Neurochemistry</i> , 2021 , 158, 539-553	6	5
29	A MDS Evidence-Based Review on Treatments for Huntington's Disease. <i>Movement Disorders</i> , 2021 ,	7	4
28	Botulinum toxin type A therapy for hemifacial spasm. <i>The Cochrane Library</i> , 2020 , 11, CD004899	5.2	4
27	Growth and renal function dynamics of renal oncocytomas in patients on active surveillance. <i>BJU International</i> , 2021 , 128, 722-727	5.6	4
26	Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntington's disease. <i>PLoS ONE</i> , 2020 , 15, e0233820	3.7	3
25	Brain-derived neurotrophic factor in cerebrospinal fluid and plasma is not a biomarker for Huntington's disease. <i>Scientific Reports</i> , 2021 , 11, 3481	4.9	3
24	Strategies to minimize placebo effects in research investigations. <i>International Review of Neurobiology</i> , 2020 , 153, 49-70	4.4	2
23	Frequency of post-stroke electroencephalographic epileptiform activity - a systematic review and meta-analysis of observational studies. <i>European Stroke Journal</i> , 2017 , 2, 361-368	5.6	2
22	Longitudinal dynamics of mutant huntingtin and neurofilament light in Huntington's disease: the prospective HD-CSF study		2

21	Prognostic value of phrenic nerve conduction study in amyotrophic lateral sclerosis: Systematic review and meta-analysis. <i>Clinical Neurophysiology</i> , 2020 , 131, 106-113	4.3	2
20	Psychogenic non-epileptic seizures in early Huntington's disease. <i>Practical Neurology</i> , 2016 , 16, 452-454	2.4	2
19	Overall Survival and Causes of Death in Neurodegeneration-An Overlooked and Underreported Theme. <i>JAMA Neurology</i> , 2017 , 74, 1379	17.2	1
18	Cerebrospinal fluid flow dynamics in Huntington's disease evaluated by phase contrast MRI. <i>European Journal of Neuroscience</i> , 2019 , 49, 1632-1639	3.5	1
17	Caffeine and Neuroprotection in Parkinson's Disease. <i>Current Topics in Neurotoxicity</i> , 2015 , 233-272		1
16	Her Aching Bones: Atypical Parathyroid Adenoma. <i>American Journal of Medicine</i> , 2016 , 129, 260-2	2.4	1
15	Mechanical Thrombectomy and Functional Outcomes After Stroke. <i>JAMA - Journal of the American Medical Association</i> , 2016 , 315, 1791-2	27.4	1
14	Management of Small Renal Masses. <i>Radiology</i> , 2018 , 289, 272-273	20.5	1
13	Perinatal insults and neurodevelopmental disorders may impact Huntington's disease age of diagnosis. <i>Parkinsonism and Related Disorders</i> , 2018 , 55, 55-60	3.6	1
12	Safety and Feasibility of Research Lumbar Puncture in Huntington's Disease: The HDClarity Cohort and Bioresource.. <i>Journal of Huntingtons Disease</i> , 2022 , 11, 59-69	1.9	1
11	Botulinum toxin type A versus anticholinergics for cervical dystonia. <i>The Cochrane Library</i> , 2021 , 4, CD004312	3.12	0
10	Anterior ischemic optic neuropathy and hematologic malignancy: a systematic review of case reports and case series. <i>Canadian Journal of Ophthalmology</i> , 2016 , 51, 459-466	1.4	
9	D4 Prediction of huntington's disease phenotype by cerebrospinal fluid biomarkers of inflammation and cell death. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, A35.1-A35	5.5	
8	Physician perception versus true efficacy of tetrabenazine for Huntington's disease. <i>Current Medical Research and Opinion</i> , 2018 , 34, 1537-1538	2.5	
7	PO104 Placebo and nocebo responses in rls: a meta-analysis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017 , 88, A39.1-A39	5.5	
6	K4 The cost and value of a huntington's disease multidisciplinary team meeting. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, A80.2-A80	5.5	
5	Bilateral gigantic earlobe keloids. <i>Clinical Medicine</i> , 2016 , 16, 91	1.9	
4	Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntington's disease 2020 , 15, e0233820		

- 3 Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntington's disease **2020**
, 15, e0233820
- 2 Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntington's disease **2020**
, 15, e0233820
- 1 Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntington's disease **2020**
, 15, e0233820